Navigation Links
Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
Date:8/3/2009

ical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. Keryx is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in numerous adult and pediatric tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under SPA, pending commencement. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for KRX-0401, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete clinical trials for KRX-0401; the risk that the data (both safety and efficacy) from the Phase 3 study will not coincide with the d
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
2. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
3. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
5. Keryx Biopharmaceuticals Receives Nasdaq Notification
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
7. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
9. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
10. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
11. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Experience Mayan heritage and enjoy ... Package at the luxury all-inclusive AAA Five Diamond Grand ... guided on-site ecological family tour where guests learn about ... Mayan Encounter Tour at the Mayan archeological site of ... pyramid in the Yucatan and the only pyramid people ...
(Date:7/11/2014)... Fadhits.com, the distinguished wedding dress manufacturer and retailer, ... holiday dresses . To top it all off, all ... prices, up to 65% off. Clients who place orders ... , Fadhits.com is devoted to designing and selling ... global clients. All its items come with very fast ...
(Date:7/11/2014)... Emily Johnson, owner of the Portland Fit Body ... boot camp has held two charity workout events and is ... 26th, from 7:15 - 8:30 at Col Summers City Park, SE ... camp session raised $510 for Medical Teams International. Their second workout ... a Dream. On July 26th, Johnson and Portland Fit Body ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Timex, the ... the launch of the Timex Performance Network, the brand’s ... training plans, athlete testimonials, seasonal news and special product ... will capitalize on the legacy of the Timex IRONMAN ... for runners and endurance athletes nationwide. The hub will ...
(Date:7/11/2014)... HealthDay Reporter FRIDAY, July ... women who can,t cough, sneeze or laugh without losing ... stem cells to regenerate weakened urethra muscles. In ... stem cells isolated from patients, own fat tissue improved ... year. Stress incontinence affects about twice as ...
Breaking Medicine News(10 mins):Health News:Explore the Aura and Mystery of the Yucatan’s Mayan Culture with New Hotel Package at AAA Five Diamond Grand Velas Riviera Maya 2Health News:Explore the Aura and Mystery of the Yucatan’s Mayan Culture with New Hotel Package at AAA Five Diamond Grand Velas Riviera Maya 3Health News:Elegant Lace Holiday Dresses Released by Fadhits.com 2Health News:Portland Fit Body Boot Camp Invites Public to Fitness Boot Camp Session Benefiting Children’s Cancer Association 2Health News:Portland Fit Body Boot Camp Invites Public to Fitness Boot Camp Session Benefiting Children’s Cancer Association 3Health News:Timex Announces Launch of Timex Performance Network 2Health News:Stem Cells May Ease Urinary Incontinence, Study Says 2Health News:Stem Cells May Ease Urinary Incontinence, Study Says 3
... AND LA JOLLA, CA-- Dana-Farber Cancer Institute and the ... with Genentech, a wholly owned member of the Roche ... to manufacture, develop and market human monoclonal antibodies to ... viruses include the strains for the current seasonal and ...
... skins, but some restaurants and population groups also want them ... can have side effects that call into question the wisdom ... to a lesser extent contamination from heavy metals and residues ... to health. This is the conclusion of a study published ...
... , , ... Rhonda Roby , PhD, MPH, associate professor and project coordinator for ... UNT Health Science Center , was instrumental in recently identifying three ... cemetery. , The Chilean government contacted Roby in 2006 to ...
... February 8, 2010- The research group of Dr. Franois ... de Montral (IRCM), in collaboration with the team of ... of Toronto) accomplished a technical breakthrough: they mapped all ... yeast Saccharomyces cerevisiae . The method used by ...
... Michigan State University has launched the nation,s first comprehensive ... which the FBI has called "the crime of the ... to food additives to auto parts- accounts for hundreds ... a major impact on health and safety, the economy, ...
... Ohio- A fictional television drama may be more effective in ... program on the same issue, according to a new study. ... drama about a teen pregnancy felt more vulnerable two weeks ... for using birth control. However, those who watched a ...
Cached Medicine News:Health News:Study carried out into biological risks of eating reptiles 2Health News:UNT Health Science Center's Roby Helps Identify Bodies of Chile's Patio 29 2Health News:UNT Health Science Center's Roby Helps Identify Bodies of Chile's Patio 29 3Health News:Researchers map all the fragile sites of the yeast Saccharomyces cerevisiae's genome 2Health News:Researchers map all the fragile sites of the yeast Saccharomyces cerevisiae's genome 3Health News:MSU launches first anti-counterfeiting research program 2Health News:MSU launches first anti-counterfeiting research program 3Health News:TV drama can be more persuasive than news program, study finds 2Health News:TV drama can be more persuasive than news program, study finds 3Health News:TV drama can be more persuasive than news program, study finds 4
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... CAESAREA, Israel , July 10, 2014 /PRNewswire/ ... Dario™ Diabetes Management Solution, today announced the appointment ... an independent member of its Board of Directors. ... of legal and business experience to LabStyle as ... director, and legal and corporate governance expert. He ...
(Date:1/15/2014)... 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) today announced ... 2013, compared to sales of $2,202,000 for the prior year ... quarter has also shown growth over the preceding quarter,s sales, ... this fiscal year. Markets that experienced sales increases over the ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... BCR-ABL That Cause Resistance to Current ... CML and ALL ... ) today reported preliminary phase 1 data from an ongoing,trial of ... lymphocytic leukemia (Ph+ALL) who,are resistant to or intolerant of the approved ...
... Also Experienced Improved Physical Functioning, INDIANAPOLIS, June ... pain of the knee treated with 60 mg ... significant pain,reduction. Patients taking duloxetine reported significant pain ... treatment that lasted,throughout the 13-week trial.(1) Results from ...
Cached Medicine Technology:Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia 2Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia 3Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia 4Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 2Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 3Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 4Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 5
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: